Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4021034 | 0.71 | HSD11B1 (0.39) | ALDH1A1HTTKMT2AGAAHPGD | |
| SCHEMBL2557730 | 0.67 | MMP8 (0.45) | ALDH1A1HTTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL7240654 | 0.66 | SMN1; SMN2 (0.46) | ALDH1A1HTTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL7246714 | 0.63 | — | — | |
| SCHEMBL4086191 | 0.62 | FFAR1 (0.42) | ALDH1A1HTTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL28528939 | 0.62 | MAOA (0.45) | ALDH1A1HTTKMT2AGAA | |
| SCHEMBL8671567 | 0.62 | MMP8 (0.46) | ALDH1A1HTTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL13074361 | 0.61 | FFAR1 (0.41) | ALDH1A1HTTKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL3619222 | 0.61 | MAOA (0.44) | ALDH1A1HTTKMT2A | |
| SCHEMBL190205 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586462-B2 | ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2003-07-01 | — | — | US | disclosed |
| US-20020187961-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2002-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187961-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER2, PTGER1, PTGER3 | ALDH1A1 1206/4885HTT 4688/4885KMT2A 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.